These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 15792818)

  • 41. Effect of subthalamic nucleus deep brain stimulation on axial motor control and protective arm responses in Parkinson's disease.
    Visser JE; Allum JH; Carpenter MG; Esselink RA; Limousin-Dowsey P; Honegger F; Borm GF; Bloem BR
    Neuroscience; 2008 Dec; 157(4):798-812. PubMed ID: 18952153
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P
    Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson's disease using a dedicated questionnaire: a Belgian multicenter survey.
    Santens P; de Noordhout AM;
    Acta Neurol Belg; 2006 Sep; 106(3):137-41. PubMed ID: 17091617
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Family-based case-control study of cigarette smoking and Parkinson disease.
    Scott WK; Zhang F; Stajich JM; Scott BL; Stacy MA; Vance JM
    Neurology; 2005 Feb; 64(3):442-7. PubMed ID: 15699372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term follow-up study with repetitive transcranial magnetic stimulation (rTMS) in Parkinson's disease.
    Málly J; Farkas R; Tóthfalusi L; Stone TW
    Brain Res Bull; 2004 Sep; 64(3):259-63. PubMed ID: 15464863
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Environmental factors and Parkinson's disease: a case-control study in the Tuscany region of Italy.
    Nuti A; Ceravolo R; Dell'Agnello G; Gambaccini G; Bellini G; Kiferle L; Rossi C; Logi C; Bonuccelli U
    Parkinsonism Relat Disord; 2004 Dec; 10(8):481-5. PubMed ID: 15542008
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease.
    Gomez Arevalo G; Jorge R; Garcia S; Scipioni O; Gershanik O
    Mov Disord; 1997 May; 12(3):277-84. PubMed ID: 9159719
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
    Carrière N; Kreisler A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2012 Feb; 168(2):143-51. PubMed ID: 22129474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
    Waters CH; Sethi KD; Hauser RA; Molho E; Bertoni JM;
    Mov Disord; 2004 Apr; 19(4):426-32. PubMed ID: 15077240
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Progress in the basic and clinical aspects of Parkinson's disease].
    Mizuno Y
    Rinsho Shinkeigaku; 2004 Nov; 44(11):741-50. PubMed ID: 15651281
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease.
    Mann RK; Edwards R; Zhou J; Jog M; Duval C
    Clin Neurol Neurosurg; 2010 Jun; 112(5):392-9. PubMed ID: 20206438
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progression of motor impairment and disability in Parkinson disease: a population-based study.
    Alves G; Wentzel-Larsen T; Aarsland D; Larsen JP
    Neurology; 2005 Nov; 65(9):1436-41. PubMed ID: 16275832
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B; Angersbach D; Jost WH
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
    Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
    J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
    Sharma JC; Macnamara L; Hasoon M; Vassallo M; Ross I
    Parkinsonism Relat Disord; 2006 Dec; 12(8):499-505. PubMed ID: 16935018
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea.
    Fenney A; Jog MS; Duval C
    Clin Neurol Neurosurg; 2008 Feb; 110(2):160-7. PubMed ID: 18063471
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
    Cerasa A; Salsone M; Morelli M; Pugliese P; Arabia G; Gioia CM; Novellino F; Quattrone A
    Parkinsonism Relat Disord; 2013 Oct; 19(10):883-8. PubMed ID: 23769805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Smoking and tea consumption delay onset of Parkinson's disease.
    Kandinov B; Giladi N; Korczyn AD
    Parkinsonism Relat Disord; 2009 Jan; 15(1):41-6. PubMed ID: 18434232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.